Suppr超能文献

登革病毒NS4B抑制剂的发现。

Discovery of Dengue Virus NS4B Inhibitors.

作者信息

Wang Qing-Yin, Dong Hongping, Zou Bin, Karuna Ratna, Wan Kah Fei, Zou Jing, Susila Agatha, Yip Andy, Shan Chao, Yeo Kim Long, Xu Haoying, Ding Mei, Chan Wai Ling, Gu Feng, Seah Peck Gee, Liu Wei, Lakshminarayana Suresh B, Kang CongBao, Lescar Julien, Blasco Francesca, Smith Paul W, Shi Pei-Yong

出版信息

J Virol. 2015 Aug;89(16):8233-44. doi: 10.1128/JVI.00855-15.

Abstract

The four serotypes of dengue virus (DENV-1 to -4) represent the most prevalent mosquito-borne viral pathogens in humans. No clinically approved vaccine or antiviral is currently available for DENV. Here we report a spiropyrazolopyridone compound that potently inhibits DENV both in vitro and in vivo. The inhibitor was identified through screening of a 1.8-million-compound library by using a DENV-2 replicon assay. The compound selectively inhibits DENV-2 and -3 (50% effective concentration [EC50], 10 to 80 nM) but not DENV-1 and -4 (EC50,>20 M). Resistance analysis showed that a mutation at amino acid 63 of DENV-2 NS4B (a nonenzymatic transmembrane protein and a component of the viral replication complex) could confer resistance to compound inhibition. Genetic studies demonstrate that variations at amino acid 63 of viral NS4B are responsible for the selective inhibition of DENV-2 and -3. Medicinal chemistry improved the physicochemical properties of the initial “hit” (compound 1), leading to compound 14a, which has good in vivo pharmacokinetics. Treatment of DENV-2-infected AG129 mice with compound 14a suppressed viremia, even when the treatment started after viral infection. The results have proven the concept that inhibitors of NS4B could potentially be developed for clinical treatment of DENV infection. Compound 14a represents a potential preclinical candidate for treatment of DENV-2- and -3-infected patients.

摘要

登革病毒的四种血清型(DENV-1至-4)是人类中最常见的蚊媒病毒病原体。目前尚无针对登革病毒的临床批准疫苗或抗病毒药物。在此,我们报告一种螺吡唑并吡啶酮化合物,其在体外和体内均能有效抑制登革病毒。该抑制剂是通过使用DENV-2复制子试验筛选180万种化合物库而鉴定出来的。该化合物选择性抑制DENV-2和-3(50%有效浓度[EC50],10至80 nM),但不抑制DENV-1和-4(EC50,>20 μM)。抗性分析表明,DENV-2 NS4B(一种非酶跨膜蛋白,是病毒复制复合体的一个组成部分)的63位氨基酸突变可赋予对化合物抑制的抗性。遗传学研究表明,病毒NS4B的63位氨基酸变异是DENV-2和-3选择性抑制的原因。药物化学改善了初始“命中”化合物(化合物1)的理化性质,得到了化合物14a,其具有良好的体内药代动力学。用化合物14a治疗DENV-2感染的AG129小鼠可抑制病毒血症,即使在病毒感染后开始治疗也是如此。结果证明了NS4B抑制剂有可能被开发用于登革病毒感染临床治疗的概念。化合物14a是治疗DENV-2和-3感染患者的潜在临床前候选药物。

相似文献

1
Discovery of Dengue Virus NS4B Inhibitors.
J Virol. 2015 Aug;89(16):8233-44. doi: 10.1128/JVI.00855-15.
2
Characterization of a dengue NS4B inhibitor originating from an HCV small molecule library.
Antiviral Res. 2017 Nov;147:149-158. doi: 10.1016/j.antiviral.2017.10.011. Epub 2017 Oct 14.
3
Identification of a new dengue virus inhibitor that targets the viral NS4B protein and restricts genomic RNA replication.
Antiviral Res. 2013 Aug;99(2):165-71. doi: 10.1016/j.antiviral.2013.05.011. Epub 2013 Jun 2.
4
Inhibition of dengue virus by targeting viral NS4B protein.
J Virol. 2011 Nov;85(21):11183-95. doi: 10.1128/JVI.05468-11. Epub 2011 Aug 24.
5
Targeting dengue virus NS4B protein for drug discovery.
Antiviral Res. 2015 Jun;118:39-45. doi: 10.1016/j.antiviral.2015.03.007. Epub 2015 Mar 19.
7
Narasin, a novel antiviral compound that blocks dengue virus protein expression.
Antivir Ther. 2011;16(8):1203-18. doi: 10.3851/IMP1884.
9
Design, synthesis and biological evaluation of spiropyrazolopyridone derivatives as potent dengue virus inhibitors.
Bioorg Med Chem Lett. 2020 Jun 1;30(11):127162. doi: 10.1016/j.bmcl.2020.127162. Epub 2020 Mar 30.

引用本文的文献

1
Mechanistic insights into dengue virus inhibition by a clinical trial compound NITD-688.
Proc Natl Acad Sci U S A. 2025 Apr;122(13):e2426922122. doi: 10.1073/pnas.2426922122. Epub 2025 Mar 28.
4
Dengue virus: pathogenesis and potential for small molecule inhibitors.
Biosci Rep. 2024 Aug 28;44(8). doi: 10.1042/BSR20240134.
5
Dengue virus pathogenesis and host molecular machineries.
J Biomed Sci. 2024 Apr 22;31(1):43. doi: 10.1186/s12929-024-01030-9.
7
Modelling the impact of JNJ-1802, a first-in-class dengue inhibitor blocking the NS3-NS4B interaction, on in-vitro DENV-2 dynamics.
PLoS Comput Biol. 2023 Dec 6;19(12):e1011662. doi: 10.1371/journal.pcbi.1011662. eCollection 2023 Dec.
8
Development in the Inhibition of Dengue Proteases as Drug Targets.
Curr Med Chem. 2024;31(16):2195-2233. doi: 10.2174/0929867331666230918110144.
9
Molecular Mechanisms of Antiviral Agents against Dengue Virus.
Viruses. 2023 Mar 8;15(3):705. doi: 10.3390/v15030705.
10
Blocking NS3-NS4B interaction inhibits dengue virus in non-human primates.
Nature. 2023 Mar;615(7953):678-686. doi: 10.1038/s41586-023-05790-6. Epub 2023 Mar 15.

本文引用的文献

1
Lead optimization of spiropyrazolopyridones: a new and potent class of dengue virus inhibitors.
ACS Med Chem Lett. 2015 Feb 2;6(3):344-8. doi: 10.1021/ml500521r. eCollection 2015 Mar 12.
2
Targeting dengue virus NS4B protein for drug discovery.
Antiviral Res. 2015 Jun;118:39-45. doi: 10.1016/j.antiviral.2015.03.007. Epub 2015 Mar 19.
3
Mapping the Interactions between the NS4B and NS3 proteins of dengue virus.
J Virol. 2015 Apr;89(7):3471-83. doi: 10.1128/JVI.03454-14. Epub 2015 Jan 14.
4
Characterization of dengue virus NS4A and NS4B protein interaction.
J Virol. 2015 Apr;89(7):3455-70. doi: 10.1128/JVI.03453-14. Epub 2015 Jan 7.
5
Efficacy of a tetravalent dengue vaccine in children in Latin America.
N Engl J Med. 2015 Jan 8;372(2):113-23. doi: 10.1056/NEJMoa1411037. Epub 2014 Nov 3.
8
Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?
Antiviral Res. 2014 Jul;107:119-24. doi: 10.1016/j.antiviral.2014.04.008. Epub 2014 May 2.
9
Dimerization of flavivirus NS4B protein.
J Virol. 2014 Mar;88(6):3379-91. doi: 10.1128/JVI.02782-13. Epub 2014 Jan 3.
10
Live attenuated vaccine: the first clinically approved dengue vaccine?
Expert Rev Vaccines. 2014 Feb;13(2):185-8. doi: 10.1586/14760584.2014.870888. Epub 2013 Dec 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验